Developer docs
API playgroundTry for free, no card

Search company profiles

Third Rock Ventures

Full company profile

uuid00004gw

Namestring
Third Rock Ventures
Legal namestring
Third Rock Ventures
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Third Rock Ventures is an independent, Boston-headquartered venture capital firm founded in 2007 by Mark Levin, Robert Tepper and Kevin Starr, former Millennium Pharmaceuticals executives. It invests in and creates life science companies rather than only funding startups, and serves three constituencies: institutional limited partners that commit capital to dedicated life sciences funds, scientific founders who work with the firm to originate companies, and the resulting portfolio of biotechnology, medical device and diagnostics companies. The firm operates offices in Boston and San Francisco, and its website lists 62 named team members spanning partners, venture partners, advisory partners, entrepreneurs-in-residence, domain experts, principals, associates, fellows, finance, recruiting and operations.

Its core offering is a four-stage company creation process: Discover identifies emerging fields of science and medicine and develops a company concept with scientific founders and expert advisors; Launch provides the financial, technical and human resources plus interim leadership and culture; Build installs experienced management teams, board seats and partnerships; Transform brings products to patients. The firm reports more than 70 companies created and 26 products launched by portfolio companies over 18 years, including Otarmeni, INLEXZO, Aqvesme and the Jewel Patch wearable cardioverter defibrillator. An internal Platform Technologies function develops and deploys shared wet lab, data science, informatics and R&D management systems across portfolio companies and seed projects, while portfolio companies are supported with executive search, recruiting and board-level business development.

Economically the firm operates as a classic venture manager: it earns recurring management fees on committed capital in dedicated life sciences funds — Fund IV ($616 million, 2016), Fund V ($770 million, 2019) and Fund VI ($1.1 billion, 2022) — plus carried interest on realized gains, and returns equity stakes through exits, IPOs and follow-on sales, including Eli Lilly's $2.88 billion acquisition of Merida Biosciences, UCB's agreement to acquire Candid Therapeutics for up to $2.2 billion, and Lisata Therapeutics' acquisition of Marea Therapeutics alongside a $225 million concurrent private placement in which funds may participate. Distribution is relationship-led rather than product-led: the Partner/Chief Operating Officer leads institutional fundraising and LP relationship management, deal flow is sourced from a network of scientific founders and expert advisors, and value creation is pursued through portfolio-company partnerships with large-cap biotech and pharmaceutical companies. Fee, carry and commitment terms are not publicly disclosed; they are communicated directly to limited partners, and the firm publishes no product or service pricing.

Short descriptiontext

Third Rock Ventures is an independent life sciences venture firm founded in 2007 that creates and funds biotechnology, medical device and diagnostics companies through its Discover, Launch, Build, Transform model, serving institutional limited partners, scientific founders and portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech company creation, venture capital funds, portfolio company formation, carried interest
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code3 codes
  • Other Investment Pools and Funds5259
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Financial Vehicles525990
SIC code2 codes
  • Investment Advice6282
  • Services-Management Consulting Services8742
Product category
Venture Capital / Life Sciences Investment Management
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund management fees and carried interest
TypeSubscription Recurring
Description

The firm manages dedicated life sciences venture funds (Fund IV $616 million in 2016, Fund V $770 million in 2019, Fund VI $1.1 billion in 2022), earning recurring management fees on committed capital plus carried interest on realized gains; the COO/Partner leads fundraising and manages limited partner relationships, and a dedicated finance and fund accounting team (fund reporting, tax, management company accounting) supports it.

thirdrockventures.com
2Returns from equity stakes in portfolio companies
TypeLicensing Royalties
Description

Third Rock's funds hold equity in the companies they found and build, so returns are realized through exits — recent examples include Lilly's $2.88 billion acquisition of Merida Biosciences and UCB's up-to-$2.2 billion acquisition of Candid Therapeutics — plus IPO and follow-on liquidity (e.g., Maze Therapeutics IPO and a $150 million registered offering).

pharmaphorum.com
3Financing participation in concurrent private placements
TypeTransaction Fee
Description

Third Rock-backed companies raise large private placements alongside strategic transactions (e.g., the $225 million concurrent private placement by Lisata Therapeutics on the acquisition of Marea Therapeutics), allowing funds and co-investors to participate in financing events.

ir.lisata.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Beyond Great
Description

Beyond Great is Third Rock's learning community for leaders across its portfolio, offering peer-to-peer networking plus tools and resources for building successful, sustainable companies.

thirdrockventures.com
Core offering1 text field

Third Rock Ventures is a life sciences venture capital firm that creates biotechnology companies from scratch rather than only funding existing startups. It identifies emerging scientific fields with founders and advisors (Discover), funds and staffs the new company with financial, technical and human resources while its partners serve in interim leadership roles (Launch), installs experienced management teams and continues as board members and domain experts (Build), and drives partnerships, value-creating transactions and products reaching patients (Transform). Revenue comes from management fees and carried interest on its dedicated life sciences venture funds (Fund IV $616M in 2016, Fund V $770M in 2019, Fund VI $1.1B in 2022) plus returns on equity stakes in portfolio companies and participation in concurrent private placements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Over 70 companies created with 18 years of company-creation experience
+6 more records
Product overview1 text field

Third Rock Ventures offers a single, unified company-creation service for healthcare/life-sciences ventures rather than a software platform with plug-in modules: its core offering is the "Company Creation Strategy," delivered through four sequential process modules — Discover (identifying and refining a company concept with scientific founders and advisors), Launch (funding and staffing the new company with Third Rock partners in interim leadership roles), Build (installing experienced management teams, serving as board members, and driving partnerships and value-creating transactions), and Transform (bringing products to patients, with 26 portfolio-company products launched to date). Alongside these modules, the firm operates the "Beyond Great" peer learning community and a portfolio of companies it created, including Syremis Therapeutics (mental health medicines), Azalea Therapeutics (in vivo precision genome engineering for cancer immunotherapy), Merida Biosciences (precision immunology for antibody-driven autoimmune and allergic disease), and Element Science (FDA-approved Jewel® Patch wearable cardioverter defibrillator).

Product and service10 records
1Company Creation Strategy
CategoryVenture capital / company creation service
Description

Third Rock's founding methodology for creating healthcare and life sciences companies from scratch, built on a patient-first mission and executed in four sequential stages: Discover, Launch, Build and Transform. The firm states it has created more than 70 companies with 26 launched products over 18 years of operation. It is delivered to scientific founders and investors as capital plus scientific, operational and board-level support.

2Discover
CategoryVenture capital / company creation service
Description

Collaborative, iterative search for emerging fields of science and medicine where a company concept can be developed with leading scientific founders and expert advisors, producing a clear vision and strategy with the patient front and center. Used by scientific founders and advisors to shape a company concept before capital is committed.

3Launch
CategoryVenture capital / company creation service
Description

Funding and staffing a newly conceived company with the financial, technical and human resources needed to reach critical growth milestones, with Third Rock partners serving in interim leadership roles and establishing company culture.

4Build
CategoryVenture capital / company creation service
Description

Transitioning out of interim roles to establish experienced management teams, serving as board members and domain experts, cultivating partnerships, and driving value-creating transactions across the portfolio.

5Transform
CategoryVenture capital / company creation service
Description

The stage in which portfolio companies bring products to patients; Third Rock reports that its portfolio companies have launched 26 products to date.

6Beyond Great
CategoryCommunity / learning resource offering
Description

Peer-to-peer learning community available to portfolio company leaders, providing networking and tools and resources focused on shared elements of building successful and sustainable companies.

7Syremis Therapeutics
CategoryPortfolio company (biotechnology — mental health)
Description

Third Rock-created biotechnology company developing novel medicines for mental health conditions, launched in December 2025 with a $165 million Series A financing.

8Azalea Therapeutics
CategoryPortfolio company (biotechnology — precision genomic medicine)
Description

Third Rock-created company enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo; launched in November 2025 with $82 million in financing.

9Merida Biosciences
CategoryPortfolio company (biotechnology — precision immunology)
Description

Third Rock-created company advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminates their pathogenic drivers, enabled by advances in protein engineering and immunology, targeting inadequately treated autoimmune and allergic conditions; launched with $121 million in April 2025 and acquired by Eli Lilly for $2.88 billion.

10Jewel® Patch Wearable Cardioverter Defibrillator (Element Science)
CategoryPortfolio company / marketed medical device
Description

FDA-approved wearable cardioverter defibrillator patch developed by Third Rock portfolio company Element Science, designed to protect individuals at temporary risk of sudden cardiac arrest without interrupting their lives; the first patch-based wearable defibrillator.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Project Onramp
Strategic tierMinor — Talent Pipeline Initiative For Diverse CandidatesTypeOthersAnnounced on2023-02-06
Description

Third Rock Ventures became the founding partner for Project Onramp's national expansion, announced in February 2023. The initiative supports the pipeline of diverse, untapped talent entering the biotech industry, complementing the firm's recruiting and talent strategy for portfolio companies.

thirdrockventures.com
2American Cancer Society Impact Venture Capital Arm (BrightEdge)
Strategic tierCore — Oncology-Focused Co-Investment And Innovation CollaborationTypeStrategic or Co-development PartnerAnnounced on2022-07-14
Description

Third Rock Ventures and the American Cancer Society's Impact Venture Capital arm announced a collaboration to drive innovation in oncology. The alliance links Third Rock's company creation platform with the ACS Impact VC arm's focus on cancer innovation, giving founders access to capital plus company creation support in oncology.

thirdrockventures.com
3Celgene
Strategic tierFlagship — Industry-Leading Global Strategic CollaborationTypeStrategic or Co-development Partner
Description

Cary Pfeffer, as head of Third Rock's partner development, played an instrumental role in an industry-leading global strategic collaboration between Agios (a Third Rock portfolio company) and Celgene in the field of cancer metabolism. The relationship illustrates the firm's ability to bring major biotech and pharmaceutical companies into collaborations with its portfolio.

thirdrockventures.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Flagship Pioneering
TypeDirect peer
Description

Boston-based life sciences company-creation firm that originates, builds and scales new companies from scientific hypotheses alongside venture investment. It matches Third Rock on operating model, customer base of scientific founders, target life sciences stages and reliance on strategic exits.

2Foresite Capital
TypeDirect peer
Description

San Francisco venture firm investing at all stages of life sciences with a dedicated company-creation practice that builds companies with founders and scientific advisors. Comparable to Third Rock in biotech focus, founder-centric origination and mixed fund/creation economics.

3Arch Venture Partners
TypeDirect peer
Description

Life sciences investor operating dedicated company-creation funds alongside traditional venture funds, originating and building companies from novel scientific platforms. It competes with Third Rock for founder relationships and for multi-hundred-million-dollar biotech financings.

4Versant Ventures
TypeDirect peer
Description

Cambridge, Massachusetts investor focused exclusively on creating and funding biotechnology companies from inception, with an internal network of operating advisors and specialized funds. Its geography, biotech-only mandate and company-creation model closely parallel Third Rock's.

55AM Ventures
TypeDirect peer
Description

Early-stage life sciences venture firm that also builds companies with scientific founders, combining funds with hands-on operating and formation support. Comparable to Third Rock in healthcare focus, stage and company-creation-led value proposition.

6Lux Capital
TypeDirect peer
Description

Investor in emerging science and deep technology that routinely forms new companies with scientific founders and provides operating leadership. Overlaps with Third Rock's Discover-to-Transform creation process and its scientific talent bench.

7Atlas Venture
TypeDirect peer
Description

Long-established healthcare and life sciences venture firm based in Boston and Cambridge that both funds and builds companies with founders and executives. Comparable on life sciences specialization, company-creation orientation, LP base and strategic-exit driven returns.

8Deerfield Management
TypeBroad incumbent
Description

Specialist healthcare investment firm with dedicated company-creation and growth vehicles alongside traditional venture funds, competing for the same therapeutic franchises and founder relationships. It is larger and more broadly diversified across healthcare than Third Rock's biotech-only model.

9RA Capital Management
TypeBroad incumbent
Description

Large specialist healthcare venture investor with deep clinical-stage portfolios and a strong follow-on funding model. It overlaps on investors, therapeutic focus and financing stages but does not compete for founder-driven company creation in the same way as Third Rock.

10GV
TypeBroad incumbent
Description

Large global venture platform with one of the industry's largest life sciences practices, providing capital and partnership support to biotech companies. It overlaps with Third Rock on biotech funding and strategic collaborations, but its portfolio spans many technology sectors rather than company-creation-only life sciences.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles27 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment160 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Third Rock Ventures

Venture Capital / Life Sciences Investment Managementthirdrockventures.com

Third Rock Ventures is an independent life sciences venture firm founded in 2007 that creates and funds biotechnology, medical device and diagnostics companies through its Discover, Launch, Build, Transform model, serving institutional limited partners, scientific founders and portfolio companies.

What Third Rock Ventures does

Third Rock Ventures is an independent, Boston-headquartered venture capital firm founded in 2007 by Mark Levin, Robert Tepper and Kevin Starr, former Millennium Pharmaceuticals executives. It invests in and creates life science companies rather than only funding startups, and serves three constituencies: institutional limited partners that commit capital to dedicated life sciences funds, scientific founders who work with the firm to originate companies, and the resulting portfolio of biotechnology, medical device and diagnostics companies. The firm operates offices in Boston and San Francisco, and its website lists 62 named team members spanning partners, venture partners, advisory partners, entrepreneurs-in-residence, domain experts, principals, associates, fellows, finance, recruiting and operations.

Its core offering is a four-stage company creation process: Discover identifies emerging fields of science and medicine and develops a company concept with scientific founders and expert advisors; Launch provides the financial, technical and human resources plus interim leadership and culture; Build installs experienced management teams, board seats and partnerships; Transform brings products to patients. The firm reports more than 70 companies created and 26 products launched by portfolio companies over 18 years, including Otarmeni, INLEXZO, Aqvesme and the Jewel Patch wearable cardioverter defibrillator. An internal Platform Technologies function develops and deploys shared wet lab, data science, informatics and R&D management systems across portfolio companies and seed projects, while portfolio companies are supported with executive search, recruiting and board-level business development.

Economically the firm operates as a classic venture manager: it earns recurring management fees on committed capital in dedicated life sciences funds — Fund IV ($616 million, 2016), Fund V ($770 million, 2019) and Fund VI ($1.1 billion, 2022) — plus carried interest on realized gains, and returns equity stakes through exits, IPOs and follow-on sales, including Eli Lilly's $2.88 billion acquisition of Merida Biosciences, UCB's agreement to acquire Candid Therapeutics for up to $2.2 billion, and Lisata Therapeutics' acquisition of Marea Therapeutics alongside a $225 million concurrent private placement in which funds may participate. Distribution is relationship-led rather than product-led: the Partner/Chief Operating Officer leads institutional fundraising and LP relationship management, deal flow is sourced from a network of scientific founders and expert advisors, and value creation is pursued through portfolio-company partnerships with large-cap biotech and pharmaceutical companies. Fee, carry and commitment terms are not publicly disclosed; they are communicated directly to limited partners, and the firm publishes no product or service pricing.

Third Rock Ventures firmographics

Firmographics
Name
Third Rock Ventures
Legal name
Third Rock Ventures
Website
https://thirdrockventures.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Third Rock Ventures is an independent life sciences venture firm founded in 2007 that creates and funds biotechnology, medical device and diagnostics companies through its Discover, Launch, Build, Transform model, serving institutional limited partners, scientific founders and portfolio companies.
Ownership category
akta.pro rank

Third Rock Ventures industry classification

Industry
Product category
Venture Capital / Life Sciences Investment Management
NAICS
Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
SIC
Investment Advice (6282), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Life sciences venture capital
  • Biotech company creation
  • Venture capital funds
  • Portfolio company formation
  • Carried interest

Where Third Rock Ventures is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Third Rock Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Fund management fees and carried interest: The firm manages dedicated life sciences venture funds (Fund IV $616 million in 2016, Fund V $770 million in 2019, Fund VI $1.1 billion in 2022), earning recurring management fees on committed capital plus carried interest on realized gains; the COO/Partner leads fundraising and manages limited partner relationships, and a dedicated finance and fund accounting team (fund reporting, tax, management company accounting) supports it.
  2. Returns from equity stakes in portfolio companies: Third Rock's funds hold equity in the companies they found and build, so returns are realized through exits — recent examples include Lilly's $2.88 billion acquisition of Merida Biosciences and UCB's up-to-$2.2 billion acquisition of Candid Therapeutics — plus IPO and follow-on liquidity (e.g., Maze Therapeutics IPO and a $150 million registered offering).
  3. Financing participation in concurrent private placements: Third Rock-backed companies raise large private placements alongside strategic transactions (e.g., the $225 million concurrent private placement by Lisata Therapeutics on the acquisition of Marea Therapeutics), allowing funds and co-investors to participate in financing events.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Third Rock Ventures product offering

Product offering

Core offering

Third Rock Ventures is a life sciences venture capital firm that creates biotechnology companies from scratch rather than only funding existing startups. It identifies emerging scientific fields with founders and advisors (Discover), funds and staffs the new company with financial, technical and human resources while its partners serve in interim leadership roles (Launch), installs experienced management teams and continues as board members and domain experts (Build), and drives partnerships, value-creating transactions and products reaching patients (Transform). Revenue comes from management fees and carried interest on its dedicated life sciences venture funds (Fund IV $616M in 2016, Fund V $770M in 2019, Fund VI $1.1B in 2022) plus returns on equity stakes in portfolio companies and participation in concurrent private placements.

Product overview

Third Rock Ventures offers a single, unified company-creation service for healthcare/life-sciences ventures rather than a software platform with plug-in modules: its core offering is the "Company Creation Strategy," delivered through four sequential process modules — Discover (identifying and refining a company concept with scientific founders and advisors), Launch (funding and staffing the new company with Third Rock partners in interim leadership roles), Build (installing experienced management teams, serving as board members, and driving partnerships and value-creating transactions), and Transform (bringing products to patients, with 26 portfolio-company products launched to date). Alongside these modules, the firm operates the "Beyond Great" peer learning community and a portfolio of companies it created, including Syremis Therapeutics (mental health medicines), Azalea Therapeutics (in vivo precision genome engineering for cancer immunotherapy), Merida Biosciences (precision immunology for antibody-driven autoimmune and allergic disease), and Element Science (FDA-approved Jewel® Patch wearable cardioverter defibrillator).

Differentiator

Problem solved

Functional benefit

Brands

  • Beyond Great: Beyond Great is Third Rock's learning community for leaders across its portfolio, offering peer-to-peer networking plus tools and resources for building successful, sustainable companies.

Products and services

  • Company Creation Strategy Third Rock's founding methodology for creating healthcare and life sciences companies from scratch, built on a patient-first mission and executed in four sequential stages: Discover, Launch, Build and Transform. The firm states it has created more than 70 companies with 26 launched products over 18 years of operation. It is delivered to scientific founders and investors as capital plus scientific, operational and board-level support.
  • Discover Collaborative, iterative search for emerging fields of science and medicine where a company concept can be developed with leading scientific founders and expert advisors, producing a clear vision and strategy with the patient front and center. Used by scientific founders and advisors to shape a company concept before capital is committed.
  • Launch Funding and staffing a newly conceived company with the financial, technical and human resources needed to reach critical growth milestones, with Third Rock partners serving in interim leadership roles and establishing company culture.
  • Build Transitioning out of interim roles to establish experienced management teams, serving as board members and domain experts, cultivating partnerships, and driving value-creating transactions across the portfolio.
  • Transform The stage in which portfolio companies bring products to patients; Third Rock reports that its portfolio companies have launched 26 products to date.
  • Beyond Great Peer-to-peer learning community available to portfolio company leaders, providing networking and tools and resources focused on shared elements of building successful and sustainable companies.
  • Syremis Therapeutics Third Rock-created biotechnology company developing novel medicines for mental health conditions, launched in December 2025 with a $165 million Series A financing.
  • Azalea Therapeutics Third Rock-created company enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo; launched in November 2025 with $82 million in financing.
  • Merida Biosciences Third Rock-created company advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminates their pathogenic drivers, enabled by advances in protein engineering and immunology, targeting inadequately treated autoimmune and allergic conditions; launched with $121 million in April 2025 and acquired by Eli Lilly for $2.88 billion.
  • Jewel® Patch Wearable Cardioverter Defibrillator (Element Science) FDA-approved wearable cardioverter defibrillator patch developed by Third Rock portfolio company Element Science, designed to protect individuals at temporary risk of sudden cardiac arrest without interrupting their lives; the first patch-based wearable defibrillator.

Quantifiable outcome

  • Over 70 companies created with 18 years of company-creation experience
  • +6 more outcomes

Companies that use Third Rock Ventures

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Third Rock Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Third Rock Ventures partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor — talent pipeline initiative for diverse candidates, core — oncology-focused co-investment and innovation collaboration and flagship — industry-leading global strategic collaboration.

  • Project Onrampminor — talent pipeline initiative for diverse candidatesOthers · 6 February 2023Third Rock Ventures became the founding partner for Project Onramp's national expansion, announced in February 2023. The initiative supports the pipeline of diverse, untapped talent entering the biotech industry, complementing the firm's recruiting and talent strategy for portfolio companies.
  • American Cancer Society Impact Venture Capital Arm (BrightEdge)core — oncology-focused co-investment and innovation collaborationStrategic or Co-development Partner · 14 July 2022Third Rock Ventures and the American Cancer Society's Impact Venture Capital arm announced a collaboration to drive innovation in oncology. The alliance links Third Rock's company creation platform with the ACS Impact VC arm's focus on cancer innovation, giving founders access to capital plus company creation support in oncology.
  • Celgeneflagship — industry-leading global strategic collaborationStrategic or Co-development PartnerCary Pfeffer, as head of Third Rock's partner development, played an instrumental role in an industry-leading global strategic collaboration between Agios (a Third Rock portfolio company) and Celgene in the field of cancer metabolism. The relationship illustrates the firm's ability to bring major biotech and pharmaceutical companies into collaborations with its portfolio.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Third Rock Ventures competitors and assessment

Company assessment

Direct peers

  • Flagship Pioneering: Boston-based life sciences company-creation firm that originates, builds and scales new companies from scientific hypotheses alongside venture investment. It matches Third Rock on operating model, customer base of scientific founders, target life sciences stages and reliance on strategic exits.
  • Foresite Capital: San Francisco venture firm investing at all stages of life sciences with a dedicated company-creation practice that builds companies with founders and scientific advisors. Comparable to Third Rock in biotech focus, founder-centric origination and mixed fund/creation economics.
  • Arch Venture Partners: Life sciences investor operating dedicated company-creation funds alongside traditional venture funds, originating and building companies from novel scientific platforms. It competes with Third Rock for founder relationships and for multi-hundred-million-dollar biotech financings.
  • Versant Ventures: Cambridge, Massachusetts investor focused exclusively on creating and funding biotechnology companies from inception, with an internal network of operating advisors and specialized funds. Its geography, biotech-only mandate and company-creation model closely parallel Third Rock's.
  • 5AM Ventures: Early-stage life sciences venture firm that also builds companies with scientific founders, combining funds with hands-on operating and formation support. Comparable to Third Rock in healthcare focus, stage and company-creation-led value proposition.
  • Lux Capital: Investor in emerging science and deep technology that routinely forms new companies with scientific founders and provides operating leadership. Overlaps with Third Rock's Discover-to-Transform creation process and its scientific talent bench.
  • Atlas Venture: Long-established healthcare and life sciences venture firm based in Boston and Cambridge that both funds and builds companies with founders and executives. Comparable on life sciences specialization, company-creation orientation, LP base and strategic-exit driven returns.

Broad incumbents

  • Deerfield Management: Specialist healthcare investment firm with dedicated company-creation and growth vehicles alongside traditional venture funds, competing for the same therapeutic franchises and founder relationships. It is larger and more broadly diversified across healthcare than Third Rock's biotech-only model.
  • RA Capital Management: Large specialist healthcare venture investor with deep clinical-stage portfolios and a strong follow-on funding model. It overlaps on investors, therapeutic focus and financing stages but does not compete for founder-driven company creation in the same way as Third Rock.
  • GV: Large global venture platform with one of the industry's largest life sciences practices, providing capital and partnership support to biotech companies. It overlaps with Third Rock on biotech funding and strategic collaborations, but its portfolio spans many technology sectors rather than company-creation-only life sciences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Third Rock Ventures social profiles

Digital presence

Third Rock Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Third Rock Ventures leadership team

Management profile

Number of profiles

Profiles27 records

Third Rock Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Third Rock Ventures M&A and investment

M&A and investment

M&A

Investments160 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Third Rock Ventures

What does Third Rock Ventures do?

Third Rock Ventures is a life sciences venture capital firm that creates biotechnology companies from scratch rather than only funding existing startups. It identifies emerging scientific fields with founders and advisors (Discover), funds and staffs the new company with financial, technical and human resources while its partners serve in interim leadership roles (Launch), installs experienced management teams and continues as board members and domain experts (Build), and drives partnerships, value-creating transactions and products reaching patients (Transform). Revenue comes from management fees and carried interest on its dedicated life sciences venture funds (Fund IV $616M in 2016, Fund V $770M in 2019, Fund VI $1.1B in 2022) plus returns on equity stakes in portfolio companies and participation in concurrent private placements.

Is Third Rock Ventures a public or private company?

Third Rock Ventures is a private company. It is classified as venture growth investor backed and is currently operating.

When was Third Rock Ventures founded?

Third Rock Ventures was founded in 2007. It employs 101 to 250 people.

Where is Third Rock Ventures based?

Third Rock Ventures is headquartered in Boston, United States, in the North America region.

How does Third Rock Ventures make money?

Three revenue lines are on record. Fund management fees and carried interest is the primary driver. The others are returns from equity stakes in portfolio companies and financing participation in concurrent private placements.

Who are Third Rock Ventures's main competitors?

Direct peers on record are Flagship Pioneering, Foresite Capital, Arch Venture Partners, Versant Ventures, 5AM Ventures, Lux Capital and Atlas Venture. Broad incumbents are Deerfield Management, RA Capital Management and GV.

Does Third Rock Ventures have an API?

No public API is recorded for Third Rock Ventures.

What industry is Third Rock Ventures in?

Third Rock Ventures's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterFunnel Biosciences secures up to $2.16B ceal with Third RockFunnel Biosciences announced a strategic research collaboration with Third Rock Ventures, focusing on biopharmaceutical development using Funnel's AI antibody platform. The deal includes platform usage fees and potential payments up to approximately $2.16 billion, subject to conditions.AETOSWireStealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune DiseaseThird Rock Ventures and Parse Biosciences announced a collaboration to build a 5 million TCR atlas for T-cell mediated autoimmune disease. The atlas will be generated using Parse's GigaLab platform, aiming to accelerate precision medicine development for underserved patients.BioSpaceLisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private PlacementLisata Therapeutics acquired Marea Therapeutics and raised approximately $225 million in a private placement. The combined company will focus on Marea's MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly, with Phase 2b and Phase 2 trials expected to report topline data in Q4 2027.pharmaphorumAcquisitive Lilly offers $2.88bn for Merida BioEli Lilly agreed to acquire immunology firm Merida Biosciences for $2.88 billion, including cash and milestones. The deal gives Lilly rights to MER511 for Graves' disease and thyroid eye disease, with completion expected in Q4. This is Lilly's ninth acquisition of 2026, bringing M&A spending near $29 billion.Investing.comThird Rock Ventures V, L.P. director sells $7.4m Septerna shares By Investing.comThird Rock Ventures V, L.P. sold approximately 147,200 shares of Septerna, Inc. on August 12, 2026, totaling roughly $7.4 million in transactions executed under a pre-arranged trading plan. The sale occurred near the stock's 52-week high, coinciding with positive analyst sentiment driven by progress in Septerna’s clinical trials for hypoparathyroidism and competitor setbacks.Investing.comThird Rock Ventures V, L.P. director sells $7.4m Septerna shares By Investing.comOn August 12, 2026, a director of Third Rock Ventures V, L.P. sold 147,200 shares of Septerna, Inc. for approximately $7.4 million as part of a pre-arranged trading plan. The sale occurred while Septerna's share price has seen significant momentum, reflecting a 281% increase over the past year. The stock is currently trading near its fair value, with analysts raising price targets based on the company's clinical trial progress and competitive landscape.Venture Capital Access OnlineFlare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics closed an $85 million Series C financing led by Third Rock Ventures and Nextech Invest, appointing Anna Protopapas as CEO. Proceeds will advance FX-111, an ARON degrader for prostate cancer, with FDA IND clearance and expected Phase 1A in Q3 2026.BioPharma DiveRapport ‘fully prepared’ to launch seizure drug solo, CEO saysRapport Therapeutics, a biotech company formed in 2023 through a collaboration between Third Rock Ventures and Johnson & Johnson's venture capital arm, is advancing RAP-219, a first-of-its-kind epilepsy medication targeting the TARPγ8 protein, into a late-stage Phase 3 program after reporting a 78% reduction in clinical seizure frequency in Phase 2 trials. CEO Abraham Ceesay stated the company is fully prepared to commercialize the drug independently, bucking the industry "sell the launch" trend given neuroscience's track record of successful small-company commercial launches. The company is also exploring a potential China partnership to expand its global development program while maintaining control over capital allocation and building a strong independent board.The Motley FoolRapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials NearOn April 17, 2026, Third Rock Ventures V, L.P., a major shareholder of Rapport Therapeutics, Inc., sold 426,005 shares in an open-market transaction valued at approximately $17.18 million, representing 5.3% of its total position in the company. The disposition was executed under a pre-planned Rule 10b5-1 trading plan, with the seller retaining approximately $266.42 million in direct holdings post-transaction. Rapport Therapeutics, whose stock has surged 230% over the past year, reported Phase 2a results showing a 90% median reduction in clinical seizures for its lead candidate RAP-219, with two Phase 3 trials expected to begin in the second quarter.Investing.comThird Rock Ventures sells $17.1m in Rapport Therapeutics stock By Investing.comThird Rock Ventures sold approximately $17.1 million worth of Rapport Therapeutics stock on April 17, 2026, disposing of 426,005 shares at prices ranging from $40.00 to $40.79 per share through a Rule 10b5-1 trading plan adopted in November 2025. The sale follows a 256% return for the biotech stock over the past year, with the stock currently trading at $36.95. Rapport Therapeutics also reported positive Phase 2a trial results for its epilepsy treatment RAP-219 and plans to accelerate Phase 3 studies to Q2 2026, drawing analyst Buy ratings with price targets of $44 to $56.